CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 277 filers reported holding CLOVIS ONCOLOGY INC in Q2 2017. The put-call ratio across all filers is 0.51 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2018 | $270,000 | -35.4% | 9,184 | 0.0% | 0.02% | -54.5% |
Q2 2018 | $418,000 | -13.8% | 9,184 | 0.0% | 0.03% | +13.8% |
Q1 2018 | $485,000 | -22.4% | 9,184 | 0.0% | 0.03% | -29.3% |
Q4 2017 | $625,000 | -17.4% | 9,184 | 0.0% | 0.04% | +7.9% |
Q3 2017 | $757,000 | -12.0% | 9,184 | 0.0% | 0.04% | -17.4% |
Q2 2017 | $860,000 | +47.0% | 9,184 | 0.0% | 0.05% | +15.0% |
Q1 2017 | $585,000 | +186.8% | 9,184 | +100.0% | 0.04% | +185.7% |
Q4 2016 | $204,000 | -51.7% | 4,592 | 0.0% | 0.01% | -54.8% |
Q3 2015 | $422,000 | -66.3% | 4,592 | -67.7% | 0.03% | -64.4% |
Q2 2015 | $1,251,000 | +224.9% | 14,235 | +67.6% | 0.09% | +222.2% |
Q3 2014 | $385,000 | +9.4% | 8,495 | 0.0% | 0.03% | +12.5% |
Q2 2014 | $352,000 | -40.1% | 8,495 | 0.0% | 0.02% | -36.8% |
Q1 2014 | $588,000 | -31.5% | 8,495 | -40.3% | 0.04% | -29.6% |
Q4 2013 | $858,000 | -0.8% | 14,235 | 0.0% | 0.05% | 0.0% |
Q3 2013 | $865,000 | -9.2% | 14,235 | 0.0% | 0.05% | -3.6% |
Q2 2013 | $953,000 | – | 14,235 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 814,833 | $45,630,648,000 | 43.63% |
EcoR1 Capital, LLC | 384,348 | $21,523,000 | 10.89% |
Palo Alto Investors LP | 2,102,857 | $117,760,000 | 6.91% |
NEA Management Company, LLC | 2,279,781 | $127,668,000 | 6.19% |
Redmile Group, LLC | 721,632 | $40,411,000 | 4.40% |
Opaleye Management Inc. | 140,000 | $7,840,000 | 3.96% |
CLIFTON PARK CAPITAL MANAGEMENT, LLC | 790,555 | $44,271,000 | 2.63% |
SUFFOLK CAPITAL MANAGEMENT LLC | 339,327 | $19,002,000 | 2.31% |
PFM Health Sciences, LP | 1,725,126 | $96,607,000 | 2.26% |
HARBOURVEST PARTNERS LLC | 51,037 | $2,858,000 | 1.50% |